Maximize the Clinical Potential of Your Antibody-Drug Conjugate at World ADC Asia

Developed with Remegen, Eisai and Regeneron the 2nd World ADC Asia is the definite ADC forum which curates the leading companies from Asia and the rest of the world focused on antibody-drug conjugate development.

Across 3 days, with 120+ ADC experts, this comprehensive antibody-drug conjugates conference will enable you to propel your ADC pipeline into clinical development. You’ll explore lessons learned from working with regulatory bodies, reviewing latest phase I clinical readouts and confidently optimize ADC CMC processes to improve your manufacturing programs. Not only will World ADC Asia delve into general antibody-drug conjugate challenges is will also focus on challenges and opportunities specific to development within Asia.

Attend World ADC Asia to network with potential collaborators, foster new connections and further cement existing partnerships. This is the only ADC focused conference that will bring together all the key players within antibody-drug conjugates in Asia.

“I gained a lot from World ADC Asia - a very impressive conference”

Hangzhou HealSun Biopharm Co., Ltd

“I was impressed by many of the speakers and learnt a significant amount, which I was able to bring back to our discovery team”

Eisai

“World ADC is the largest conference with an exclusive focus on ADC. It is an excellent chance to assess the field’s direction and meet with other ADC companies”

Tanabe Research Laboratories